[go: up one dir, main page]

MX2009011312A - Vaccination regimen for b-cell vaccines. - Google Patents

Vaccination regimen for b-cell vaccines.

Info

Publication number
MX2009011312A
MX2009011312A MX2009011312A MX2009011312A MX2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A MX 2009011312 A MX2009011312 A MX 2009011312A
Authority
MX
Mexico
Prior art keywords
treatment
cell vaccines
hapten
vaccination regimen
specific
Prior art date
Application number
MX2009011312A
Other languages
Spanish (es)
Inventor
Martin Bachmann
Patrik Maurer
Philipp Mueller
Thomas Pfister
Wolfgang Renner
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38669515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011312(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of MX2009011312A publication Critical patent/MX2009011312A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibodyresponses in a vaccinated subject. The invention further provides a method forprevention or treatment of a disease by inducing hapten-specific antibodiesin asubject comprising administering into said subject acomposition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.
MX2009011312A 2007-04-20 2008-04-18 Vaccination regimen for b-cell vaccines. MX2009011312A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106676A EP1982729A1 (en) 2007-04-20 2007-04-20 Vaccination Regimen for B-Cell Vaccines
PCT/EP2008/054775 WO2008129020A1 (en) 2007-04-20 2008-04-18 Vaccination regimen for b-cell vaccines

Publications (1)

Publication Number Publication Date
MX2009011312A true MX2009011312A (en) 2009-11-05

Family

ID=38669515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011312A MX2009011312A (en) 2007-04-20 2008-04-18 Vaccination regimen for b-cell vaccines.

Country Status (12)

Country Link
US (2) US20100119540A1 (en)
EP (2) EP1982729A1 (en)
JP (1) JP2010524901A (en)
CN (1) CN101678097A (en)
AU (1) AU2008240670A1 (en)
BR (1) BRPI0810088A2 (en)
CA (1) CA2683520A1 (en)
CL (1) CL2008001113A1 (en)
MX (1) MX2009011312A (en)
RU (1) RU2009142690A (en)
TW (1) TW200902058A (en)
WO (1) WO2008129020A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP2338510A1 (en) * 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
EA030813B1 (en) 2010-05-26 2018-10-31 Селекта Байосайенсиз, Инк Methods of generating an antibody immune response and enhancing local induction of immune cytokines when using synthetic nanocarriers coupled with adjuvants
MX2013012596A (en) 2011-04-29 2014-08-21 Selecta Biosciences Inc SYNTHETIC TOLEROGENIC NANOPORTERS TO GENERATE CD8 + T REGULATORS LYMPHOCYTES.
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250106B2 (en) * 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
MXPA04006617A (en) * 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Method of preparing and using a bivalent vaccine against morphine/heroin addiction.
US20060111271A1 (en) * 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
WO2007100755A1 (en) * 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation

Also Published As

Publication number Publication date
WO2008129020A1 (en) 2008-10-30
AU2008240670A1 (en) 2008-10-30
RU2009142690A (en) 2011-05-27
JP2010524901A (en) 2010-07-22
BRPI0810088A2 (en) 2014-10-21
US20100119540A1 (en) 2010-05-13
CA2683520A1 (en) 2008-10-30
EP2148699A1 (en) 2010-02-03
CL2008001113A1 (en) 2008-12-19
CN101678097A (en) 2010-03-24
US20120258130A1 (en) 2012-10-11
TW200902058A (en) 2009-01-16
EP1982729A1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
MX2021008224A (en) Combination of vaccination and inhibition of the pd-1 pathway.
EP4523756A3 (en) Immunotherapeutic vaccine and antibody combination therapy
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
PH12016500040A1 (en) Pcsk9 vaccine
IN2014DN08830A (en)
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MX2013004817A (en) INFLAMMATORY DISEASE.
MX2013007657A (en) Immunostimulatory oligodeoxynucleotides.
IN2012DN02736A (en)
MX337723B (en) IgE CH3 PEPTIDE VACCINE.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MA32819B1 (en) VACCINE COMBINALLY COMBINED AGAINST ACELLULAR POULTRY
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
EA201171032A1 (en) TREATMENT SCHEMES WITH THE HELP OF VACCINE AGAINST FLU, ASSOCIATED WITH PANDEMIC STRAINS
MX2009011312A (en) Vaccination regimen for b-cell vaccines.
TW200731986A (en) Use of vaccines for the treatment/prevention of the transmission of pathogens
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
EP4509185A3 (en) Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
WO2008067995A8 (en) Means and method for raising improved immune response
WO2009117365A3 (en) Vaccine compositions for inducing immune responses against components of drusen
WO2007147518A3 (en) Use of ppd for the adjuvantation of a nucleic acid vaccine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal